Novel bis-platinum complexes endowed with an improved pharmacological profile

Molecular Pharmaceutics

Volumn 7, Issue 1, 2010, Pages 207-216

  Gatti, Laura ^a   Perego, Paola ^a   Leone, Roberto ^b   Apostoli, Piero ^c   Carenini, Nives ^a   Corna, Elisabetta ^a   Allievi, Cecilia ^d   Bastrup, Ulla ^d   De Munari, Sergio ^d   Di Giovine, Stefano ^d   Nicoli, Paola ^d   Grugni, Mario ^d   Natangelo, Marco ^d   Pardi, Gianluca ^d   Pezzoni, Gabriella ^d   Singer, Jack W ^d   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d Cell Therapeutics Inc   (Italy)

Author keywords

Antitumor efficacy; Bis platinum complexes; Drug development; Plasma binding

Indexed keywords

[[MU (1,8,11,18 TETRAAZAOCTADECANE N 1,N 18) BIS[TRANS DIAMINO(BUTYRATO O)PLATINUM]]TETRADODECYLSULFATE; [[MU (1,8,11,18 TETRAAZAOCTADECANE N 1,N 18) BIS[TRANS DIAMINO(BUTYRATO O)PLATINUM]]TETRANITRATE; [[MU (1,8,11,18 TETRAAZAOCTADECANE N 1,N 18) BIS[TRANS DIAMINO(CAPRONATO O)PLATINUM]]TETRADODECYLDULFATE; [[MU (1,8,11,18 TETRAAZAOCTADECANE N 1,N 18) BIS[TRANS DIAMINO(CAPRONATO O)PLATINUM]]TETRANITRATE; BBR 3464; CARBOPLATIN; CISPLATIN; CT 3610; CT 47463; CT 47518; OXALIPLATIN; PLATINUM COMPLEX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BASE MISPAIRING; CANCER INHIBITION; CELL CYCLE; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DEGRADATION KINETICS; DNA BINDING; DRUG ACCUMULATION; DRUG BINDING; DRUG DESIGN; DRUG EFFICACY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LUNG CARCINOMA; MISMATCH REPAIR; MOUSE; NONHUMAN; OVARY CARCINOMA; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; DNA ADDUCTS; DNA MISMATCH REPAIR; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; DRUG STABILITY; FEMALE; HUMANS; MICE; MICE, NUDE; ORGANOPLATINUM COMPOUNDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 76249088329     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900211j     Document Type: Article

References (24)

1. Judson, I.; Kelland, L. R. New developments and approaches in the platinum arena. Drugs 2000, 4, 29-36.
2. Agarwal, R.; Kaye, S. B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 2003, 3, 502-516.
3. Farrell, N. New platinum-based drugs in cancer therapy; Humana Press Inc.: Totowa, NJ, 2000; pp 321-338.
4. Kelland, L. R. New platinum-based drugs in cancer therapy; Humana Press Inc.: Totowa, NJ, 2000; pp 299-319.
5. Pratesi, G.; Perego, P.; Polizzi, D.; Righetti, S. C.; Supino, R.; Caserini, C.; Manzotti, C.; Giuliani, F. C.; Pezzoni, G.; Tognella, S.; Spinelli, S.; Farrell, N.; Zunino, F. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts. Br. J. Cancer 1999, 80, 1912-1919.
6. Gatti, L.; Beretta, G. L.; Carenini, N.; Corna, E.; Zunino, F.; Perego, P. Gene expression profiles in the cellular response to a multinuclear platinum complex. Cell. Mol. Life Sci. 2004, 61, 973-981.
7. Sessa, C.; Capri, G.; Gianni, L.; Peccatori, F.; Grasselli, G.; Bauer, J.; Zucchetti, M.; Vigano, L.; Gatti, A.; Minoia, C.; Liati, P.; Van den Bosch, S.; Bernareggi, A.; Camboni, G.; Marsoni, S. Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex. Ann. Oncol. 2000, 11, 977-983.
8. Farrell, N. Polynuclear platinum drugs. Met. Ions Biol. Syst. 2004, 42, 251-296.
9. Gourley, C.; Cassidy, J.; Edwards, C.; Samuel, L.; Bisset, D.; Camboni, G.; Young, A.; Boyle, D.; Jodrell, D. A phase I study of the trinuclear platinum compound, BBR3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer. Cancer Chemother. Pharmacol. 2004, 53, 95-101.
10. Jodrell, D.; Evans, T.; Steward, W.; Cameron, D.; Prendiville, J.; Aschele, C.; Noberasco, C.; Lind, M.; Carmichael, J.; Dobbs, N. Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma. Eur. J. Cancer 2004, 40, 1872-1877.
11. Hensing, T. A.; Hanna, N. H.; Gillenwater, H. H.; Camboni, G. M.; Allevi, C.; Socinski, M. A. Phase II study of BBR3464 as treatment in patients with sensitive or refractory small cell lung cancer. Anticancer Drugs 2006, 17, 697-704.
12. Lanzi, C.; Perego, P.; Supino, R.; Romanelli, S.; Pensa, T.; Carenini, N.; Viano, I.; Colangelo, D.; Leone, R.; Apostoli, P.; Cassinelli, G.; Gambetta, R. A.; Zunino, F. Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance. Biochem. Pharmacol. 1998, 55, 1247-1254.
13. Perego, P.; Gatti, L.; Caserini, C.; Supino, R.; Colangelo, D.; Leone, R.; Spinelli, S.; Farrell, N.; Zunino, F. The cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells. J. Inorg. Biochem. 1999, 77, 59-64.
14. Perego, P.; Gatti, L.; Righetti, S. C.; Beretta, G. L.; Carenini, N.; Corna, E.; Dal Bo, L.; Tinelli, S.; Colangelo, D.; Leone, R.; Apostoli, P.; Lombardi, L.; Beggiolin, G.; Piazzoni, L.; Zunino, F. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells. Int. J. Cancer 2003, 105, 617-624.
15. Benedetti, V.; Perego, P.; Beretta, G. L.; Corna, E.; Tinelli, S.; Righetti, S. C.; Leone, R.; Apostoli, P.; Lanzi, C. Zunino F Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds. Mol. Cancer Ther. 2008, 7, 679-687.
16. Perego, P.; Righetti, S. C.; Supino, R.; Delia, D.; Caserini, C.; Carenini, N.; Bedogné, B.; Broome, E.; Krajewski, S.; Reed, J. C.; Zunino, F. Role of apoptosis and apoptosis-related proteins in the cisplatin-resistant phenotype of human tumor cell lines. Apoptosis 1997, 2, 540-548.
17. Martelli, L.; Di Mario, F.; Ragazzi, E.; Apostoli, P.; Leone, R.; Perego, P.; Fumagalli, G. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells. Biochem. Pharmacol. 2006, 72, 693-700.
18. Aebi, S.; Kurdi-Haidar, B.; Gordon, R.; Cenni, B; Zheng, H.; Fink, D.; Christen, R. D.; Boland, C. R.; Koi, M.; Fishel, R.; Howell, S. B. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 1996, 56, 3087-3090.
19. Anthoney, D. A.; McIlwrath, A. J.; Gallagher, W. M.; Edlin, A. R.; Brown, R. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistance tumor cells. Cancer Res. 1996, 56, 1374-1381.
20. Gatti L.; Perego P. Cellular resistance to oxaliplatin and drug accumulation defects. In Platinum and other heavy metal compounds in Cancer Chemotherapy. Cancer drug discovery and development; Bonetti, A., Leone, R., Muggia, F. R., Howell, S. B., Eds.; Humana Press: New York, 2009; pp 115-123.
21. Perego, P.; Romanelli, S.; Carenini, N.; Magnani, I.; Leone, R.; Bonetti, A.; Paolicchi, A.; Zunino, F. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol. Ann. Oncol. 1998, 9, 423-430.
22. Marqués-Gallego, P.; Kalayda, G. V.; Jaehde, U.; den Dulk, H.; Brouwer, J.; Reedijk, J. Cellular accumulation and DNA platination of the new platinum(II) anticancer compounds based on anthracene derivatives as carrier ligands. J. Inorg. Biochem. 2009, 103, 791-796.
23. Farrell, N.; De Almeida, S.; Skov, K. Bis(platinum) complexes containing two platinum cis-diammine units. Synthesis and initial DNA-binding studies. J. Am. Chem. Soc. 1988, 110, 5018-5019.
24. Roberts, J.; Peroutka, J.; Farrell, N. Cellular pharmacology of polynuclear platinum anti-cancer agents. J. Inorg. Biochem. 1999, 77, 51-57.